|Bid||1.35 x 28000|
|Ask||1.40 x 900|
|Day's Range||1.35 - 1.45|
|52 Week Range||1.35 - 3.25|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 24, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
Every investor in Versartis Inc (NASDAQ:VSAR) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owningRead More...
The Menlo Park, California-based company said it had a loss of 27 cents per share. In the final minutes of trading on Tuesday, the company's shares hit $1.78. A year ago, they were trading at $17.95. _____ ...
The transaction offers Versartis stockholders a significant ownership stake in a promising company with a novel approach for treating a variety of resistant or metastatic cancers, as well as the talent and financial resources to advance the development program to important inflection points,” said Jay Shepard, Chief Executive Officer. On June 3, 2018, Versartis and Aravive Biologics, Inc. entered into a definitive agreement under which Aravive will merge with a wholly owned subsidiary of Versartis in an all-stock transaction. The transaction has been unanimously approved by the boards of directors of both companies and is subject to approval by the stockholders of both companies.
Versartis (VSAR) stock rose 48.3% in the week of June 1–8. Versartis had consistent growth during the week, with 6.9% and 9.7% growth on June 4 and June 5, respectively. VSAR stock has risen ~50.9% over the last month. On June 4, Versartis entered into a merger agreement with Aravive Biologics.
LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want access to our free research report on Sarepta Therapeutics, Inc. (NASDAQ: SRPT), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SRPT as the Company's latest news hit the wire. On June 01, 2018, the Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion against approval for EXONDYS® (eteplirsen) for treatment of patients with Duchenne muscular dystrophy (DMD).
LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want a free Stock Review on VSAR sign up now at www.wallstequities.com/registration. This Tuesday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Versartis Inc. (NASDAQ: VSAR), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), 22nd Century Group Inc. (NYSE AMER: XXII), and Abeona Therapeutics Inc. (NASDAQ: ABEO).
The Menlo Park, California-based company said it had a loss of 25 cents per share. The company's shares closed at $1.50. A year ago, they were trading at $17.50. _____ This story was generated by Automated ...
Versartis Inc (NASDAQ:VSAR) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
On a per-share basis, the Menlo Park, California-based company said it had net income of 87 cents. The biopharmaceutical company posted revenue of $40,000 in the period. For the year, the company reported ...
Investors in Versartis (VSAR) need to pay close attention to the stock based on moves in the options market lately.
NEW YORK, NY / ACCESSWIRE / December 4, 2017 / It was an exciting day for biotech companies Ampio Pharmaceuticals and Versartis. Both stocks had big closes in the green. Ampio has engaged with LaVoieHealthScience ...
The Menlo Park, California-based company said it had a loss of $1.40 per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...